Daewoong Pharmaceuticals announces US clinical trial result on Nabota at Dubai Derma and spurs exportation

Daewoong Pharmaceuticals announces US clinical trial result on Nabota at Dubai Derma and spurs exportation Announced clinical trial result and informed the excellence of Nabota to Middle East and Northern Africa Strong standing with botulinum toxin through global conferences and exhibitions From 12th to 14th of last month, Daewoong Pharmaceuticals participated in Dubai Derma 2016 held in Dubai International Expo and announced the US clinical trial result on Nabota, aggressively engaging in overseas markets. In its 16th year, Dubai Derma 2016 is the largest dermatology and laser conference and exhibition in the Middle East and North America participated by over 700 brands with over 10,000 visitors from around the world. In this conference, 230 renowned dermatologists presented on botulinum toxin, peeler and laser, sharing their latest knowledge and information on the issues. In this event, Daewoong Pharmaceuticals announced the US clinical trial result on Nabota and promoted its products from its booth. During the workshop session, Prof. Jonghyeon Won from Seoul Asan Hospital in Korea announced various results of clinical trials on Nabota. He said, “Nabota contains high content of 19S form which, due to its high level purification process, exhibits the fasted result most stably. This had been proved in Korean clinical trials and was reconfirmed by various other clinical trials including the most recent US phase 3 clinical trial. Director Jeonghoon Seok, who presented on the various methods to apply Nabota, stated, “Many doctors from Middle East and Europe asked questions about the clinical trial results of Nabota and the latest techniques using Nabota. I was able to again realize their interest in the advanced toxin technology of Korea.” Daewoong Pharmaceuticals is expanding its overseas sales routes through strategic PR activities by presenting in global conferences and symposiums. On 7th of last month, Daewoong Pharmaceuticals announced the US phase 3 clinical trial results on Nabota at ASAPS held in Las Vegas. They are making a headway with their goal to release Nabota in US and Europe by 2017. Release in 2013, Nabota was continuously signed in export contracts across over 60 countries in North and South America, Europe, Middle East and Southeast Asia worth over 7,000 billion won. *Photo : At Dubai Derma 2016 held from 12 to 14 of last month, Daewoong Pharmaceuticals is introducing Nabota to the visitors.

The release as fetched from its publisher. daewoong.co.kr ↗